CIK 0001042418 · Non-accelerated filer<br>Smaller reporting company
Inhibitor Therapeutics, Inc.
Sign in to watch- Ticker
- INTI
- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 541641133
- Phone
- (813) 766-2462
- Business address
- 4830 W. KENNEDY BLVD., SUITE 600, TAMPA, FL, 33609
- Former names
- HedgePath Pharmaceuticals, Inc., COMMONWEALTH BIOTECHNOLOGIES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 78 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-01-10 | Mayne Pharma Ventures Pty Ltd 10% owner | Purchase · Series B Convertible Preferred Stock | +3,478,261 | 3,478,261 | ||
| 2018-01-10 | Mayne Pharma Ventures Pty Ltd 10% owner | Purchase · Series A Warrants to Purchase Common Stock | +2,608,696 | 2,608,696 | ||
| 2018-01-10 | Mayne Pharma Ventures Pty Ltd 10% owner | Purchase · Series B Warrants to Purchase Common Stock | +2,608,696 | 2,608,696 | ||
| 2017-12-19 | Cross Stefan Director | Purchase | −600,000 | $162,660.00 | $97.6B | 0 |
| 2017-12-19 | Mayne Pharma Ventures Pty Ltd 10% owner | Purchase | +600,000 | $162,660.00 | $97.6B | 198,106,132 |
| 2017-06-30 | HedgePath, LLC 10% owner | Sale | −2,500,000 | 79,627,069 | ||
| 2017-05-04 | Martin Robert Daniel Director | Grant or award · Restricted Stock Units | +60,000 | 60,000 | ||
| 2017-05-04 | MAGRAB E. BRENDAN Chairman of the Board | Grant or award · Restricted Stock Units | +65,000 | 65,000 | ||
| 2017-03-08 | Watson W. Mark Director | Option exercise | +300,000 | 310,000 | ||
| 2017-03-08 | Watson W. Mark Director | Shares withheld for taxes | −118,800 | $0.34 | $40K | 191,200 |
| 2017-03-08 | Watson W. Mark Director | Option exercise | +400,000 | 591,200 | ||
| 2017-03-08 | Watson W. Mark Director | Shares withheld for taxes | −158,400 | $0.34 | $54K | 432,800 |
| 2017-03-08 | Watson W. Mark Director | Option exercise | +200,000 | 632,800 | ||
| 2017-03-08 | Watson W. Mark Director | Shares withheld for taxes | −79,200 | $0.34 | $27K | 553,600 |
| 2017-03-08 | Watson W. Mark Director | Option exercise · Restricted Stock Units | −300,000 | 0 | ||
| 2017-03-08 | Watson W. Mark Director | Option exercise · Restricted Stock Units | −400,000 | 0 | ||
| 2017-03-08 | Watson W. Mark Director | Option exercise · Restricted Stock Units | −200,000 | 0 | ||
| 2017-03-08 | Hasara Garrison J. CFO and Treasurer | Option exercise | +3,500,000 | 3,500,000 | ||
| 2017-03-08 | Hasara Garrison J. CFO and Treasurer | Shares withheld for taxes | −1,470,478 | $0.34 | $500K | 2,029,522 |
| 2017-03-08 | Hasara Garrison J. CFO and Treasurer | Option exercise | +3,500,000 | 5,529,522 |
Page 4 of 9 · 165 trades